The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
68 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $107,253,601 in first-year total cost, median $823,295.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BBBP-B (55)]25
- Special Emphasis Panel[ZRG1 BBBP-H (55)]22
- Special Emphasis Panel[ZRG1 BBBP-Z (55)]7
- Special Emphasis Panel[ZRG1 BBBP-B (52)]6
- Special Emphasis Panel[ZRG1 BBBP-J (90)]4
Most frequent institutions
- JOHNS HOPKINS UNIVERSITY6
- UNIVERSITY OF CALIFORNIA, SAN DIEGO6
- UNIVERSITY OF ARIZONA3
- WAKE FOREST UNIVERSITY HEALTH SCIENCES3
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | ACTIVE MIND: An adaptive clinical trial of cognitive training to improve function and delay dementia1R01AG075014-01A1 | EDWARDS, JERRI | UNIVERSITY OF SOUTH FLORIDA, FL | $5,508,175 | ZRG1 |
| 2022 | Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.1R01AG074983-01 | AGADJANYAN, MICHAEL GSCHNEIDER, LON SSULTZER, DAVID | INSTITUTE FOR MOLECULAR MEDICINE, CA | $2,680,709 | ZRG1 |
| 2022 | Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)1R01AG076660-01 | VONGPATANASIN, WANPENZHANG, RONGZHU, DAVID C | UT SOUTHWESTERN MEDICAL CENTER, TX | $2,369,453 | ZRG1 |
| 2022 | Arterial Stiffness, Cognition, and Equol (ACE)1R01AG074971-01 | SEKIKAWA, AKIRA | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $2,257,337 | ZRG1 |
| 2022 | Communication Bridge: A person-centered Internet-based intervention for individuals with primary progressive aphasia2R56AG055425-06 | ROBERTS, ANGELA CHRISTINEROGALSKI, EMILY J | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $2,184,811 | LCOM |
| 2022 | PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial1R01AG075122-01 | BRINTON, ROBERTA EILEENHERNANDEZ, GERSON DAVIDMOSCONI, LISA | UNIVERSITY OF ARIZONA, AZ | $2,121,223 | ZRG1 |
| 2022 | First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers1R01AG076565-01 | ERHARDT, WILLIAM A. | OLIGOMERIX, INC, NY | $1,917,889 | ZRG1 |
| 2022 | Phase II clinical trial of transcranial direct current stimulation in the treatment of primary progressive aphasia1R01AG075111-01A1 | HAMILTON, ROY HTSAPKINI, KYRANA | UNIVERSITY OF PENNSYLVANIA, PA | $1,500,901 | LCOM |
| 2022 | Optimizing a closed-loop digital meditation intervention for remediating cognitive decline and reducing stress in older adults1R01AG076668-01 | GAZZALEY, ADAM HZIEGLER, DAVID A | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,362,781 | ZRG1 |
| 2022 | Early Age-Related Hearing Loss Investigation (EARHLI): A Randomized Controlled Trial to Assess Mechanisms Linking Early Age-Related Hearing Loss and Alzheimer's Disease and Related Dementias1R01AG075083-01A1 | GOLUB, JUSTIN SCOTT | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $1,076,743 | ZRG1 |
| 2022 | Determinants of Individual Differences in the Efficacy of Aerobic Exercise to Improve Brain Health and Reduce Alzheimer Disease Risk in Older African Americans1R01AG078211-01 | GLUCK, MARK A | RUTGERS THE STATE UNIV OF NJ NEWARK, NJ | $953,835 | ZRG1 |
| 2022 | Targeting language-specific and executive-control networks with transcranial direct current stimulation in aphasic AD1R01AG075404-01A1 | TSAPKINI, KYRANA | JOHNS HOPKINS UNIVERSITY, MD | $828,275 | CNN |
| 2022 | Addressing Hearing Loss as a Common Unmet Contributor to Neuropsychiatric Symptoms1R01AG076525-01 | NIEMAN, CARRIE LOH, ESTHER SEUNGHEE | JOHNS HOPKINS UNIVERSITY, MD | $818,314 | ZRG1 |
| 2022 | Establishing the optimal frequency of dance movement for neurocognitive and physical outcomes in people at risk of Alzheimer's disease1R01AG076669-01 | HUGENSCHMIDT, CHRISTINA ESORIANO, CHRISTINA T | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $782,691 | ZRG1 |
| 2022 | Intermittent Hypoxia Training: A Novel Therapy for Mild Cognitive Impairment1R01AG076675-01 | SHI, XIANGRONG | UNIVERSITY OF NORTH TEXAS HLTH SCI CTR, TX | $733,970 | ZRG1 |
| 2022 | Adaptive Neuromodulation of Working Memory Networks in Aging and Dementia1R01AG075417-01A1 | DAVIS, SIMON W | DUKE UNIVERSITY, NC | $733,471 | ZRG1 |
| 2022 | Assessment of Language and Cognition in Older Deaf Signers1R01AG074928-01 | GOLLAN, TAMAR | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $657,027 | ZRG1 |
| 2022 | Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease1R01AG065171-01A1 | MUNRO, CYNTHIA ANN | JOHNS HOPKINS UNIVERSITY, MD | $656,300 | ZRG1 |
| 2022 | Language Switching with Alzheimer's Disease1R01AG076415-01 | GOLLAN, TAMAR | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $631,730 | ZRG1 |
| 2022 | Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity (EXEC-study)1R01AG076456-01 | BRONAS, ULF G | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $508,214 | ZRG1 |
| 2021 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies1R01AG071643-01 | CAGGIANO, ANTHONY OGALVIN, JAMES EHAMBY, MARY E | COGNITION THERAPEUTICS, INC., PA | $10,764,669 | ZRG1 |
| 2021 | A Single Ascending Dose / Multiple Ascending Dose Phase I study of the GSM 776890 in healthy normal subjects1R01AG070353-01 | GALASKO, DOUGLAS RWAGNER, STEVEN LEE | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $3,156,733 | ZRG1 |
| 2021 | Food Effect study and drug supply scale-up for PTI-1251R01AG067972-01A1 | BURNS, LINDSAY H | CASSAVA SCIENCES, INC, TX | $2,710,220 | ZRG1 |
| 2021 | Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease1R01AG074447-01 | MAHER, PAMELA ANNERASCHKE, WILLIAM C | VIROGENICS, INC., CA | $2,503,169 | ZRG1 |
| 2021 | Mechanisms, response heterogeneity and dosing from MRI-derived electric field models in tDCS augmented cognitive training: a secondary data analysis of the ACT study1RF1AG071469-01 | FANG, RUOGUWOODS, ADAM J. | UNIVERSITY OF FLORIDA, FL | $2,180,958 | ZRG1 |
| 2021 | BEACH: Biomarker and Edema Attenuation in IntraCerebral Hemorrhage Phase 2a Trial1R01AG069930-01 | HANLEY, DANIEL FVAN ELDIK, LINDA J | JOHNS HOPKINS UNIVERSITY, MD | $2,078,174 | ZRG1 |
| 2021 | First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)1R01AG071810-01 | YOLES, ETI | IMMUNOBRAIN CHECKPOINT INC., NY | $1,984,624 | ZRG1 |
| 2021 | A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease1R01AG073177-01 | MECCA, ADAM PETER | YALE UNIVERSITY, CT | $1,967,865 | ZRG1 |
| 2021 | Differential Effects of Exercise Modality on Cognition and Brain in Older Adults1R01AG070036-01 | SZABO-REED, AMANDA N.VIDONI, ERIC DENNIS | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $1,375,262 | ZRG1 |
| 2021 | Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease1R01AG071151-01 | POTTER, HUNTINGTONPRESSMAN, PETER SCOTT | UNIVERSITY OF COLORADO DENVER, CO | $1,340,244 | ZRG1 |
| 2021 | A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease1R01AG071656-01 | TUSZYNSKI, MARK H. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,201,473 | ZRG1 |
| 2021 | Novel food-based approach for prevention of age-associated cognitive decline inolder adults with obesity1R56AG065236-01A1 | COHEN, RONALD ADAS, SAI KRUPAFRANCESCHINI, MARIA ANGELAROBERTS, SUSAN B | TUFTS UNIVERSITY BOSTON, MA | $1,189,438 | ZRG1 |
| 2021 | RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (Rest)1R01AG071522-01 | GREENBERG, BARRY DAVIDROSENBERG, PAUL B | JOHNS HOPKINS UNIVERSITY, MD | $785,568 | ZRG1 |
| 2021 | A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease1R01AG071074-01A1 | BHASIN, SHALENDERMARSHALL, GAD ASHER | BRIGHAM AND WOMEN'S HOSPITAL, MA | $752,126 | ZRG1 |
| 2021 | Objectively Measured Sedentary Behavior and Physical Activity in PREVENTABLE Study1R01AG074592-01 | BEDDHU, SRINIVASAN | UNIVERSITY OF UTAH, UT | $740,106 | ZRG1 |
| 2021 | Repurposing Siponimod for Alzheimer's Disease1R01AG073212-01 | DECOURT, BORISSABBAGH, MARWAN NOELWILSON, JEFFREY R | CLEVELAND CLINIC LERNER COM-CWRU, OH | $731,856 | ZRG1 |
| 2021 | Slow-wave sleep enhancement in those at risk for Alzheimer's disease: Links with memory, excitotoxicity, and plasma A-beta1R01AG068001-01A1 | WILCKENS, KRISTINE ANN | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $720,431 | ZRG1 |
| 2021 | PATH-Pain: A Primary Care-Based Psychosocial Intervention To Improve Cognitive and Depression Outcomes in Older Adults with MCI and Early Stage AD1R01AG070055-01A1 | KIOSSES, DIMITRIS NRAVDIN, LISA DREID, MANNEY CARRINGTON | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $718,167 | ZRG1 |
| 2021 | Compensation Training and Lifestyle Modifications to promote healthy aging in persons at risk for Alzheimer's disease: a digital application supported intervention1R01AG066748-01A1 | SCHMITTER-EDGECOMBE, MAUREENTOMASZEWSKI-FARIAS, SARAH E | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $692,048 | ZRG1 |
| 2021 | Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP1R01AG073482-01 | BOXER, ADAM L.LJUBENKOV, PETER ALEXANDER | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $677,137 | ZRG1 |
| 2021 | Modulation of Hippocampal Circuitry and Memory Function with Focused Ultrasound in Amnestic MCI1R01AG073480-01 | BOOKHEIMER, SUSAN Y | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $621,961 | ZRG1 |
| 2021 | Clinical trial of vestibular therapy to reduce falls in patients with Alzheimer's disease1R01AG065259-01A1 | AGRAWAL, YURI | JOHNS HOPKINS UNIVERSITY, MD | $523,611 | ZRG1 |
| 2021 | Practice effects of daily functioning across the Alzheimer’s disease spectrum1R01AG073261-01 | DUFF, KEVIN M | UNIVERSITY OF UTAH, UT | $478,400 | ZRG1 |
| 2020 | A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients1R01AG068268-01 | BERNICK, CHARLESHUA, XUEMOEBIUS, HANS JOERG | ATHIRA PHARMA, INC., WA | $7,811,344 | ZRG1 |
| 2020 | The POINTER Neurovascular Ancillary Study1R01AG066910-01 | BRINKLEY, TINA ESHALTOUT, HOSSAM | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $2,474,352 | ZRG1 |
| 2020 | Targeted physical and cognitive activity in a VR environment in older adults at risk for Alzheimer's disease1R01AG065356-01 | PA, JUDY | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $1,406,971 | ZRG1 |
| 2020 | Reducing African Americans' Alzheimer's Disease Risk Through Exercise-MCI Cohort (RAATE-MCI)1R01AG067765-01 | CARMICHAEL, OWEN T.NEWTON, ROBERT LEE | LSU PENNINGTON BIOMEDICAL RESEARCH CTR, LA | $968,867 | ZRG1 |
| 2020 | Neurocognitive Impairment Assessment in Symptomatic Carotid Occlusion Recanalized Endovascularly: NIA SCORE1R01AG065238-01 | HASAN, DAVID M. | UNIVERSITY OF IOWA, IA | $886,752 | ZRG1 |
| 2020 | Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)1R01AG068248-01 | CASSANO, PAOLOIOSIFESCU, DAN VLADOSORIO, RICARDO S | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $873,715 | ZRG1 |
| 2020 | Cognitive and Physical Exercise to Improve Outcomes after Surgery in the Elderly1R01AG061161-01A1 | HUGHES, CHRISTOPHER | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $841,781 | ZRG1 |
| 2020 | Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease1R01AG068260-01 | MASDEU, JOSEPH CSEKHAR, RAJAGOPAL VISWANATH | BAYLOR COLLEGE OF MEDICINE, TX | $808,231 | ZRG1 |
| 2020 | Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: A Randomized Clinical Trial1R01AG065467-01 | ROVNER, BARRY W. | THOMAS JEFFERSON UNIVERSITY, PA | $779,451 | ZRG1 |
| 2020 | Enhancement of Hippocampal Plasticity Using Repetitive Transcranial Magnetic Stimulation1R01AG062543-01A1 | CHOU, YING-HUI | UNIVERSITY OF ARIZONA, AZ | $735,123 | ZRG1 |
| 2020 | The Use of Deferiprone to Improve Subarachnoid Hemorrhage Cognitive Outcome: U-DISCO1R01AG068848-01A1 | HASAN, DAVID M.TORNER, JAMES CTRANEL, DANIEL T.ZANATY, MARIO | UNIVERSITY OF IOWA, IA | $727,973 | ZRG1 |
| 2020 | Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease1R01AG063925-01A1 | MALHOTRA, ATUL | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $726,355 | ZRG1 |
| 2020 | Enhancing gamma band response to improve working memory in individuals with mild cognitive impairment1R01AG065252-01 | SINGH, FIZA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $721,636 | ZRG1 |
| 2020 | Citalopram as a posterior cortical protective therapy in Parkinson disease1R01AG065246-01A1 | KOTAGAL, VIKAS | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $709,919 | ZRG1 |
| 2020 | Yoga, Aerobic and Stretching Exercise Effects on Neurocognitive Performance: A Randomized Controlled Trial1R01AG066630-01 | GOTHE, NEHA PRAVIN | UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, IL | $697,729 | ZRG1 |
| 2020 | Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia1R01AG066670-01 | DU, FEIFORESTER, BRENT PETER | MCLEAN HOSPITAL, MA | $561,552 | ZRG1 |
| 2020 | Promoting Reengagement in Daily Meaningful Activity Intervention for Adults with Mild Cognitive Impairment and Their Caregivers1R01NR018162-01A1 | LU, YUEH-FENG YVONNE | INDIANA UNIVERSITY INDIANAPOLIS, IN | $554,750 | ZRG1 |
| 2020 | Testing the Efficacy of FFC-AC-EIT in Patients with Alzheimers Disease and Related Dementias1R01AG065338-01 | BOLTZ, MARIERESNICK, BARBARA | UNIVERSITY OF MARYLAND BALTIMORE, MD | $505,805 | ZRG1 |
| 2019 | Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial1R01AG063826-01 | BRINTON, ROBERTA EILEENRODGERS, KATHLEEN E.SCHNEIDER, LON S | UNIVERSITY OF ARIZONA, AZ | $8,410,912 | ZRG1 |
| 2019 | Establishing the science behind Alzheimer's recruitment registries: opportunities for increasing diversity and accelerating enrollment into trials1R01AG063954-01 | BLEAKLEY, AMYLANGBAUM, JESSICA BROOKE | BANNER HEALTH, AZ | $1,458,714 | ZRG1 |
| 2019 | POINTER-zzz: Sleep Ancillary to U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk of Alzheimer's Disease1R01AG064440-01 | BAKER, LAURA D.HAYDEN, KATHLEEN M | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $1,370,747 | ZRG1 |
| 2019 | Modulation effects of Baduanjin mind-body exercise on subjective cognitive decline1R01AG063975-01 | KONG, JIAN | MASSACHUSETTS GENERAL HOSPITAL, MA | $813,924 | ZRG1 |
| 2019 | The Promotion of Physical Activity for the Prevention of Alzheimer's Disease in Adults with Down Syndrome1R01AG063909-01 | DONNELLY, JOSEPH E.PTOMEY, LAUREN TAYLOR | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $762,834 | ZRG1 |
| 2019 | Revitalizing Cognition in Older Adults at Risk for Alzheimer's Disease with Near-Infrared Photobiomodulation1R01AG064587-01 | ALEXANDER, GENE EBOWERS, DAWNWOODS, ADAM J. | UNIVERSITY OF FLORIDA, FL | $738,176 | ZRG1 |
| 2019 | Treating primary progressive aphasia and elucidating neurodegeneration in the language network using transcranial direct current stimulation1R01AG059763-01A1 | HAMILTON, ROY H | UNIVERSITY OF PENNSYLVANIA, PA | $727,899 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.